Biosimilars Market

1
Biosimilars Market To Reach USD 44.56 Billion By
2026
2
High target disease prevalence, product launches,
emerging market players, and drug development
pressure on pharmaceuticals due to upcoming
patent expiries are key factors contributing to
high CAGR of Biosimilars during forecast
period.Market Size USD 5.10 Billion in 2018,
Market Growth - CAGR of 30.8, Market Trends
Product launches and research for advanced
Biosimilars According to the current analysis
of Reports and Data, the global Biosimilars
market was valued at USD 5.10 Billion in 2018 and
is expected to reach USD 44.56 Billion by year
2026, at a CAGR of 30.8. Biosimilar are
alternatives to existing patented, and approved
biologicss and possess similar medicinal
properties as compared to the original biologics.
The biosimilars vary a little from original
biologics in terms of structure but must have
similar safety and efficacy as compared to the
originator biologics. Biosimilars development
does not require Phase II clinical trial for
approval and the focus is put on determination of
biosimilarity to the reference originator
biologics. Thus it has much reduced clinical
development timelines and reduced product costs
as compared to use of original biologics.
Market Summary
www.reportsanddata.com
3

• Further key findings from the report suggest
• Recombinant Peptides segment was estimated to
  account for USD 501.00 million in 2018 and is
  expected to grow reach USD 4.38 Billion by year
  2026.
• As of 2018, Recombinant Non-glycosylated Proteins
  is the dominating Biosimilars which holds over
  60 of the global market. European regional
  market is the chief revenue generating source for
  this product segment, followed by North America
  and Asia-Pacific regions.
• Biosimilars market is growing at a CAGR of 2 in
  Asia Pacific followed by North America and
  Europe, with 21.0 and 31.4 CAGR, respectively.
  High chronic disease prevalence across the globe
  is the key factor to accelerate the market growth
  during forecast period across all regions.
• Recombinant Glycosylated Proteins is expected to
  be the fastest growing market segment during
  forecast period 2019-2026 with a CAGR of 33.4.
  However, regulatory obstacles and manufacturing
  complexity are major challenge for the market
  growth of this market segment.
• Some regions such as U.S. and Latin America are
  facing slow adoption of biosimilars due to
  stringent regulatory framework..

4
Market Summary

• Key Players
• Amgen, Biocon, Celltrion, Dr. Reddy's
  Laboratories, Mylan, Pfizer, Samsung Biologics,
  Sandoz, Stada Arzneimittel, and Teva
  Pahrmaceutical.
• Segmentation
• For the purpose of this report, Reports and Data
  has segmented the Biosimilars market on the basis
  of type, disease type, and region
• Type (Revenue, USD Million 20162026)
• Recombinant Non-glycosylated Proteins
• Disease Type (Revenue, USD Million 20162026)
• Oncology
• Blood Disorders
• Chronic Diseases
• Autoimmune Diseases
• Growth Hormone Deficiency
• Infectious Diseases
• Other Diseases

To look at the PDF Sample Report and get 30
minutes of a free consultation _at_
https//www.reportsanddata.com/sample-enquiry-form
/1177
www.reportsanddata.com
5
Market Summary

• Disease Type (Revenue, USD Million 20162026)
• Oncology
• Blood Disorders
• Chronic Diseases
• Autoimmune Diseases
• Growth Hormone Deficiency
• Infectious Diseases
• Other Diseases
• Regional Outlook (Revenue in USD Million
  20162026)
• North America
• Europe
• Asia Pacific
• Middle East Africa
• Latin America

Grab Your Report at an Impressive Discount!
Please Click Here https//www.reportsanddata.co
m/discount-enquiry-form/1177
www.reportsanddata.com
6
The report emphasizes the following key
questions
Q.1.What are the most lucrative and promising
growth prospects for the market? Q.2.Which
sectors are expected to deliver a high growth
rate and which industry aspects come into play in
this advancement? Q.3.Which geographies are
estimated to exhibit the highest growth and the
underlying causes? Q.4.Which factors are
impacting the future of the market and what are
the driving factors? Q.5.What are the hurdles
and challenges curtailing the industrys growth
in the forecast period?
www.reportsanddata.com
7
About Us
Reports and Data is a market research and
consulting company that provides syndicated
research reports, customized research reports,
and consulting services. Our solutions purely
focus on your purpose to locate, target and
analyze consumer behavior shifts across
demographics, across industries and help clients
make a smarter business decision. We offer market
intelligence studies ensuring relevant and
fact-based research across a multiple industries
including Healthcare, Technology, Chemicals,
Power, and Energy. We consistently update our
research offerings to ensure our clients are
aware about the latest trends existent in the
market. Reports and Data has a strong base of
experienced analysts from varied areas of
expertise.
Contact Us John Watson Head of Business
Development Reports And Data Web
www.reportsanddata.com Direct Line
1-212-710-1370 E-mail sales_at_reportsanddata.com